New synthesis method imitates the way molecules were formed at the dawn of life on Earth
Researchers from the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), with support from the Nuclear Magnetic Resonance Service of the Universitat Autònoma de Barcelona (UAB) have developed a method for synthesising organic molecules very selectively, by assembling simple molecules and using an enzyme from E. coli (FSA: D-fructose-6-phosphate aldolase), which acts as a biocatalyst. This is a significant step forward since it replicates the formation of carbohydrates in conditions resembling those that presumably initiated life on the Earth (prebiotic conditions) and because it allows relatively large organic molecules to be obtained very selectively and efficiently. Furthermore, it is a process with few steps, that does not use organic solvents and generates no waste, and it has great potential in chemistry, especially for obtaining molecules and active ingredients of interest.

This is an E.coli FSA enzyme.
CSIC
Pere Clapés, a research professor with the CSIC who led this project, explains that in the synthesis of organic molecules "...it is not only important for them to have the correct structure, but also the right angle and position in space, because this affects their function". In fact, this is one of the main problems that can limit the effectiveness of compounds like drugs. In the case of pentoses and hexoses, these are simple sugars (monosaccharides) with five and six carbon atoms, respectively: crucial for life thanks to their function in energy production, structuring, communication and cell-cell recognition. The results show that the scientists obtained pentoses and hexoses by assembling formaldehyde and glycolaldehyde, with a minimal modification to the FSA enzyme sequence.
A very malleable enzyme
The enzyme FSA was discovered in 2001 and its physiological function in E. coli is still unknown. It is thought to be an ancestral enzyme, and that it is active before a broad range of compounds. What surprised the researchers is that it is a very malleable enzyme, much more so than others. As a result, with only a small number of genetic mutations in the enzyme, its catalytic capacity can be modulated and increased significantly. This is what allows the enzyme to be carefully adapted in order to synthesise several molecules at will.
The metabolism of carbohydrates in living organisms is a complex process, forged over millions of years of evolution. It is no easy task to carry out these processes in a flask, whether by assembling the enzymes involved in the process or by manipulating the metabolic pathways of living organisms. Nor is it simple to obtain carbohydrates with conventional chemical methods, which require several stages and the use of organic solvents.
The procedure was developed by scientists in the Biotransformation and Active Molecules Group of the Spanish National Research Council (CSIC), with support from the Nuclear Magnetic Resonance Service of the UAB. Pere Clapés explains: "we want to prove that the tools of biocatalysis allow complex molecules to be obtained from simpler ones, which are in fact the same ones used in nature". He goes on: "Over millions of years, living organisms have forged these metabolic strategies to obtain the carbohydrates they need to survive."
"The process is a simple one, mimicking the prebiotic formation of carbohydrates from compounds that were probably around in the world before life began", adds Teodor Parella, of the UAB.
For these researchers, the engineering of proteins, in particular of biocatalysts, has enormous potential for the sustainable synthesis of natural molecules and their derived products.
Original publication
Original publication
Anna Szekrenyi, Xavier Garrabou, Teodor Parella, Jesús Joglar, Jordi Bujons & Pere Clapés; "Asymmetric assembly of aldose carbohydrates from formaldehyde and glycolaldehyde by tandem biocatalytic aldol reactions"; Nature Chemistry; 2015
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Merck Licenses Four Oncology Research and Development Programs from Vertex - Vertex receives upfront payment of $230 million plus royalties on future sales

Artificial intelligence helps diagnose leukemia - How machine learning improves the evaluation of blood analysis data
